Kind Pharmaceutical

About Kind Pharmaceutical

Kind Pharmaceutical is a clinical-stage biopharmaceutical company established in 2014, with operations in Hangzhou, China, and San Francisco, USA. The company was founded by a group of scientists with global industry experience, including CEO Dr. Dong Liu, who previously held positions at FibroGen and Merck. Kind Pharmaceutical focuses on the research and development of innovative therapeutics for kidney diseases, various forms of anemia, and cancer.

The company's business model centers on the discovery, development, and eventual commercialization of its drug candidates. Revenue generation is anticipated through pharmaceutical sales, research collaborations, and licensing agreements. Kind Pharmaceutical targets clients such as hospitals, clinics, and healthcare providers. The company has successfully raised significant capital to fund its operations, including a $35 million Series A in 2021, a Series B in December 2021, and a Series C round of over $400 million (RMB) in November 2025. These funds are allocated to advancing clinical trials, expanding R&D capabilities, and progressing its drug pipeline.

The lead product in Kind's pipeline is AND017, an oral small-molecule compound for treating anemia associated with chronic kidney disease (CKD), sickle cell disease (SCD), and myelodysplastic syndromes (MDS). AND017 is a first-in-class hemoglobin elevating agent (HbEA) that has completed Phase II trials and initiated a Phase III trial. The U.S. FDA granted Orphan Drug Designation to AND017 for the treatment of SCD, which provides incentives like potential market exclusivity. Another key clinical candidate is AND019, a selective estrogen receptor degrader (SERD) for treating ER+/Her2- breast cancer. The company is also developing next-generation Antibody-drug conjugates (ADCs).